UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~PURSUANT TO~~Date ~~SECTION~~of 13Report ~~OR 15~~(dDate of earliest event reported): OFFebruary 9, 2010

~~THE~~VIOQUEST PHARMACEUTICALS, INC. ~~SECURITIES~~(Exact ~~EXCHANGE~~name ~~ACT~~of OFregistrant ~~1934~~as specified in its charter)

Date of Report (Date of earliest event reported): December 31, 2008


Delaware	000-16686	58-1486040
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

VioQuest Pharmaceuticals, Inc.


P.O. Box 2287 Minneapolis, MN		55402
(Address of Principal Executive Offices)		(Zip Code)

~~(Exact name~~Registrant’s oftelephone ~~registrant~~number, asincluding ~~specified~~area incode: ~~its charter~~(612) 220-3237

~~Delaware~~180 ~~(State~~Mount orAiry ~~other~~Rd., ~~jurisdiction~~Suite of102Basking ~~incorporation)~~Ridge, ~~000-16686~~NJ 07920 (~~Commission~~Former ~~File~~name ~~Number)~~or ~~58-1486040~~former ~~(IRS~~address ~~Employer~~if ~~Identification~~changed Nosince last report.)

180 Mt. Airy Road, Suite 102

Basking Ridge, NJ 07920

(Address of principal executive offices)

(908) 766-4400

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

oItem ~~Pre-commencement~~5.02 ~~communications~~Departure ~~pursuant~~of toDirectors ~~Rule~~or ~~14d-2(b)~~Certain ~~under~~Officers; ~~the~~Election ~~Exchange~~of ~~Act~~Directors; ~~(17~~Appointment ~~CFR~~of ~~240~~Certain Officers; Compensatory Arrangements of Certain Officers.~~14d-2(b))~~

oOn ~~Pre-commencement~~February 9, ~~communications~~2009, ~~pursuant~~the toboard ~~Rule~~of ~~13e-4~~directors of VioQuest Pharmaceuticals, Inc. (cthe “Company”) ~~under~~appointed Wayne W. Mills as a member of the ~~Exchange~~board ~~Act~~of ~~(17~~directors ~~CFR~~to ~~240~~fill a vacancy on the board.~~13e-4(c))~~ On such date, Stephen C. Rocamboli and Michael Weiser each tendered their resignations from the board of directors and in all other capacities with the Company, including any officer positions, effective as of the end of such day. For any additional information regarding the Company, correspondence can be sent to P.O. Box 2287, Minneapolis, Minnesota 55402, Attention: Assistant Secretary.

~~Item 5.02 Departure of Directors or Certain Officers.~~SIGNATURE

~~On December~~Pursuant ~~31,~~to ~~2008,~~the ~~Michael~~requirements ~~Becker,~~of the ~~then~~Securities ~~President~~Exchange ~~and~~Act ~~Chief Executive Officer and member~~ of 1934, the ~~Board~~Company ofhas ~~Directors~~duly ofcaused ~~VioQuest~~this ~~Pharmaceuticals,~~report ~~Inc.~~to be ~~(the~~signed ~~“Company”),~~on ~~tendered~~its ~~his~~behalf ~~resignation~~by ~~from~~the ~~each~~undersigned ofhereunto ~~those positions~~duly authorized.

~~Item~~VIOQUEST ~~8.01~~PHARMACEUTICALS, ~~Other Events~~INC.

~~On January~~Date: 15February 11, ~~2009, VioQuest Pharmaceuticals, Inc. consummated a series of~~2010 ~~transactions with Cahaba Pharmaceuticals, LLC resulting in the transfer of~~ ~~certain licenses, assets and intellectual property related to the Company’s~~ ~~product candidates Xyfid™ (1% uracil topical) and VQD-002 (triciribine phosphate~~ monohydrate), as well as a transfer of rights to any priority review voucher potentially generated from the development of Lenocta™ (sodium stibogluconate) from VioQuest to Cahaba. At closing, Cahaba remitted an aggregate of $250,000 to VioQuest and certain of its vendors and licensees. The Company may also receive future payments upon the successful achievement of specified development, regulatory and commercialization milestones and may receive royalties based on sales of any resultant products. The subject licenses were limited in scope to the North American market, with options for specified additional geographic territories under certain conditions. The Company has retained certain geographic rights to these product candidates.

~~SIGNATURE~~By: /s/ Mark D. Dacko

~~Pursuant to~~Mark ~~the~~D. ~~requirements of the Securities Exchange Act of 1934, the Registrant has~~Dacko ~~duly~~Controller ~~caused~~and ~~this~~Assistant ~~report to be signed on its behalf by the undersigned hereunto~~Secretary ~~duly authorized.~~

	VioQuest Pharmaceuticals, Inc.
Date: March 12, 2009	By:	/s/ Christopher P. Schnittker
		Christopher P. Schnittker
		Vice President &
		Chief Financial Officer

Filing Compare · VioQuest Pharmaceuticals, Inc.